In the following video, Motley Fool health-care analyst David Williamson takes a look back at Vertex's (VRTX 1.23%) earnings report this quarter. While it was far from a good quarter for the company, things were somewhat better than expected, leading to a sell-off that wasn't nearly as bad as analysts had feared. David tells us why the company struggled this quarter, and what investors can expect from them in the months to come.
Foolish Review: Vertex Earnings
By Dave Williamson – Jan 30, 2013 at 4:46PM
NASDAQ: VRTX
Vertex Pharmaceuticals
Market Cap
$108B
Today's Change
(-1.23%) $5.18
Current Price
$417.21
Price as of October 29, 2025 at 4:00 PM ET
A look at how Vertex performed this quarter.
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid